Parenteral and oral pharmacotherapy in prevention of osteoporotic fractures in postmenopausal osteoporosis

被引：1
|
作者：
Pawlak-Bus, Katarzyna [1 ,2 ]
Leszczynski, Piotr [1 ,2 ]
机构：
[1] Wielospecjalisty Szpital J Strusia, Oddzial Reumatol & Osteoporozy, PL-61001 Poznan, Poland
[2] Uniwersytet Med Karola Marcinkowskiego, Klin Reumatol & Rehabil, Pracownia Chorob Metab Kosci & Tkanki Lacznej, Poznan, Poland
来源：
PRZEGLAD MENOPAUZALNY | 2013年 / 12卷 / 03期
关键词：
postmenopausal osteoporosis; fracture prevention; bisphosphonates; denosumab; strontium ranelate; raloxifene; teriparatide;
D O I：
10.5114/pm.2013.36598
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Currently available drugs for the management of postmenopausal osteoporosis can confuse clinicians in daily practice. The number of new oral and therapeutic agents with a different mechanism of action can make a clinical decision to start more complex treatment than previously. This may confirm that in order to know how, when and whom to treat in postmenopausal osteoporosis, specific recommendations based on medical scientific evidence are needed. This manuscript offers compact and easily available information about antiresorptive drugs which can be used by physicians in clinical practice.
引用
收藏
页码：271 / 277
页数：7
相关论文
共 50 条
  • [1] PREVENTION OF OSTEOPOROSIS AND OSTEOPOROTIC FRACTURES
    CUMMINGS, SR
    NEVITT, MC
    HABER, RJ
    WESTERN JOURNAL OF MEDICINE, 1985, 143 (05): : 684 - 687
  • [2] Prevention of osteoporotic fractures in postmenopausal women
    Javid, K. S.
    Karim, M. A.
    Keenan, J.
    Ferky, H.
    Garlick, N.
    Maruthainar, N.
    MINERVA ORTOPEDICA E TRAUMATOLOGICA, 2008, 59 (06) : 343 - 354
  • [3] Management of postmenopausal osteoporosis and the prevention of fractures
    Gambacciani, M.
    Levancini, M.
    PANMINERVA MEDICA, 2014, 56 (02) : 115 - 131
  • [4] Risedronate for the prevention of fractures in postmenopausal osteoporosis
    Sickels, JM
    Nip, CS
    ANNALS OF PHARMACOTHERAPY, 2002, 36 (04) : 664 - 670
  • [5] Calcium for prevention of osteoporotic fractures in postmenopausal women
    Cumming, RG
    Nevitt, MC
    JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (09) : 1321 - 1329
  • [6] DENOSUMAB FOR PREVENTION OF FRACTURES IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Tofilovska, S. T. J.
    Prosheva, T. B. P. Bajraktarova
    Jordanova, S. J.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S457 - S458
  • [7] Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
    Cummings, Steven R.
    San Martin, Javier
    McClung, Michael R.
    Siris, Ethel S.
    Eastell, Richard
    Reid, Ian R.
    Delmas, Pierre
    Zoog, Holly B.
    Austin, Matt
    Wang, Andrea
    Kutilek, Stepan
    Adami, Silvano
    Zanchetta, Jose
    Libanati, Cesar
    Siddhanti, Suresh
    Christiansen, Claus
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08): : 756 - 765
  • [8] NICE recommendations for the prevention of osteoporotic fractures in postmenopausal women
    Delmas, Pierre D.
    Siris, Ethel S.
    BONE, 2008, 42 (01) : 16 - 18
  • [9] Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women
    Ellis, Alexandra G.
    Reginster, Jean-Yves
    Luo, Xuemei
    Bushmakin, Andrew G.
    Williams, Robert
    Sutradhar, Santosh
    Mirkin, Sebastian
    Jansen, Jeroen P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (08) : 1617 - 1626
  • [10] Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
    Wells, G.
    Cranney, A.
    Peterson, J.
    Boucher, M.
    Shea, B.
    Robinson, V
    Coyle, D.
    Tugwell, P.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (01):
12345